Enovis Corporation — Form 10-Q Summary
Reporting period: Three and nine months ended September 29, 2023. Enovis is a medical technology company operating through Prevention & Recovery and Reconstructive segments. The filing is unaudited and presents continuing operations following the April 2022 separation of ESAB Corporation.
Financial performance and metrics
- Revenue: Third-quarter net sales were $417.5 million, up 8.8% from $383.8 million; nine-month sales were $1.252 billion, up 8.5% from $1.154 billion. Growth was primarily from existing businesses, with additional contributions from acquisitions and foreign currency.
- Segment revenue: Prevention & Recovery sales increased 5.4% in the quarter and 3.8% year to date. Reconstructive sales increased 15.6% in the quarter and 17.6% year to date.
- Gross profit and margin: Third-quarter gross profit was $243.0 million, with a 58.2% margin versus 56.2% in the prior-year quarter. Nine-month gross profit was $726.4 million, with a 58.0% margin versus 55.2%.
- Operating results: GAAP operating loss was $20.5 million in the quarter and $60.0 million for the nine months, compared with losses of $17.9 million and $43.0 million, respectively, in the comparable periods.
- Net income: Net loss attributable to Enovis was $2.9 million, or $0.05 per diluted share, in the quarter, versus a $66.6 million loss, or $1.23 per share. Nine-month net loss attributable to Enovis was $36.2 million, or $0.67 per diluted share, versus net income of $25.3 million, or $0.46 per share.
- Continuing operations: Net loss from continuing operations was $19.5 million in the quarter and $56.9 million year to date. Discontinued operations contributed $16.6 million in the quarter and $21.1 million year to date, including a $15.5 million gain on the sale of a retained facility and tax-related items.
- Adjusted EBITDA: Non-GAAP Adjusted EBITDA was $65.4 million, or 15.7% of sales, in the quarter, compared with $57.2 million and 14.9%. Nine-month Adjusted EBITDA was $187.5 million, or 15.0% of sales, compared with $161.1 million and 14.0%.
- Cash flow: Operating cash flow was $66.6 million for the nine months, compared with cash used of $19.9 million in the prior-year period. Investing cash flow was negative $183.1 million, including $131.4 million for acquisitions and investments and $94.3 million for capital expenditures and intangible assets. Financing cash flow was positive $125.0 million.
- Liquidity: Cash and cash equivalents were $32.1 million at September 29, 2023, compared with $24.3 million at December 31, 2022. The company reported $505 million available under its revolving credit facility.
- Debt: Reported debt was $395.0 million, all classified as long-term, compared with $259.3 million at year-end 2022. The weighted-average borrowing rate under the credit agreement was 6.54%. Enovis was in compliance with its debt covenants at quarter-end.
- Balance sheet: Total assets were $4.401 billion and total equity was $3.442 billion. Inventories increased to $470.9 million from $426.6 million at year-end, while goodwill was $2.027 billion and intangible assets were $1.101 billion.
Material changes versus the prior comparable period
- Revenue growth reflected higher volumes, pricing actions, market outperformance in Reconstructive, acquisitions and favorable currency translation.
- Gross margin improved due to pricing, mix, operating leverage and lower inventory fair-value step-up amortization, partly offset by supply-chain inflation and unfavorable foreign currency effects.
- SG&A increased by $22.0 million in the quarter and $55.0 million year to date, driven by commissions, growth investments, medical-device-regulation costs and inflation. R&D also increased due to investment in surgical productivity and computer-assisted surgery technologies.
- Prior-year results included significant unusual items, including an ESAB investment gain or loss, an insurance settlement gain, a gain on a cost-basis investment and debt-extinguishment charges. These items materially affect year-over-year GAAP comparability.
- Novastep was acquired for $96.9 million in June 2023, and an external-fixation product line was acquired for $28.2 million in July 2023. The acquisitions expanded the Reconstructive foot-and-ankle portfolio but were modestly dilutive to current margins; management expects future accretion.
- The company extinguished its $450 million term loan during the first quarter of 2023 and funded acquisitions primarily through revolving-credit borrowings.
Guidance, outlook, risks and unusual items
- No specific quantitative revenue, earnings or margin guidance is provided in the filing text.
- Management expects sales to typically peak in the fourth quarter and believes liquidity is adequate to fund operations for the next twelve months.
- On September 22, 2023, Enovis agreed to acquire LimaCorporate for enterprise value of €800 million, comprising approximately €700 million of cash consideration and €100 million of Enovis shares. Closing was expected in the first quarter of 2024, subject to regulatory and customary conditions.
- After quarter-end, Enovis amended its credit agreement to provide a $400 million term-loan commitment and issued $460 million of 3.875% senior unsecured convertible notes due 2028. It also paid $62 million for capped-call transactions. These transactions increase financing capacity but add leverage, interest obligations, potential liquidity requirements and possible equity dilution.
- Enovis completed the $27.5 million Precision AI acquisition on October 5, 2023; results will be included beginning in the following fiscal quarter.
- Key risks include Lima closing and integration, acquisition financing and leverage, variable interest rates, foreign exchange, inflation and supply availability, medical-device regulation, product liability or recalls, reimbursement and healthcare regulation, cybersecurity, intellectual property, manufacturing disruptions and litigation.
- Contingent consideration liabilities were $26.5 million at quarter-end. Management stated that pending legal and regulatory proceedings are not expected to have a material adverse effect, although outcomes cannot be assured.
- Approximately 31% of quarterly sales and 32% of nine-month sales were generated outside the United States. A hypothetical 1% increase in interest rates would have increased interest expense by approximately $1.0 million for the quarter and $2.5 million for the nine months.
Important facts for investors to verify
- Completion timing, regulatory approval and final financing terms for the LimaCorporate acquisition.
- Post-closing leverage, covenant compliance and availability under the amended credit agreement.
- Whether organic revenue growth and Adjusted EBITDA margin improvements continue after separating acquisition effects, currency movements and pricing.
- Inventory levels, working-capital conversion and sustainability of positive operating cash flow.
- Potential dilution, cash-settlement requirements and conversion terms associated with the 2028 convertible notes.
- Integration progress and margin contribution from Novastep, Precision AI and other recent acquisitions.
- Exposure to foreign currency, medical-device-regulation costs, supply-chain inflation and contingent consideration obligations.